Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: abatacept infusion Clear all
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Rheumatoid Arthritis Memory B Cells and Abatacept

NCT03652961
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, DMARDs
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Abatacept in the Treatment of Uveitis

NCT01279954
View directory record Official record
Conditions
Uveitis
Interventions
Abatacept
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 28, 2026, 1:32 PM EDT
Recruiting Phase 3 Interventional

Abatacept in Immune Checkpoint Inhibitor Myocarditis

NCT05335928
View directory record Official record
Conditions
Myocarditis Acute, Cancer
Interventions
Abatacept plus, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
29
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Belatacept 3 Month Post Transplant Conversion Study

NCT02213068
View directory record Official record
Conditions
Transplant; Failure, Kidney, EBV
Interventions
belatacept, Tacrolimus, MPA
Drug
Lead sponsor
Lorenzo Gallon
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

NCT04046549
View directory record Official record
Conditions
Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
Interventions
Belatacept, VIB4920, Thymoglobulin, Methylprednisolone
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

NCT05822583
View directory record Official record
Conditions
COVID-19
Interventions
abatacept infusion, Placebo group
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
82
States / cities
Birmingham, Alabama • Tucson, Arizona • Davis, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

NCT04503616
View directory record Official record
Conditions
Graft-versus-host Disease
Interventions
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 28, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

NCT00534313
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
19
States / cities
Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 28, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

NCT01856257
View directory record Official record
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Belatacept Early Steroid Withdrawal Trial

NCT01729494
View directory record Official record
Conditions
Renal Transplantation
Interventions
Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
8
States / cities
San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 28, 2026, 1:32 PM EDT
Terminated Phase 2 Interventional Results available

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

NCT04472494
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Abatacept, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
44
States / cities
Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based

NCT01820572
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Belatacept, Tacrolimus, Cyclosporine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Abatacept With Methotrexate- Phase IIB

NCT00162266
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667), Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Sep 28, 2026, 1:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

NCT06145282
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Briquilimab, Filgrastim, Abatacept, Sirolimus, Cyclophosphamide
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients

NCT02103855
View directory record Official record
Conditions
Nephrotoxicity
Interventions
Belatacept
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

NCT00468208
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Abatacept
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Sep 28, 2026, 1:32 PM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 28, 2026, 1:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

NCT03714022
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
South Miami, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 28, 2026, 1:32 PM EDT
Active, not recruiting Phase 2 Interventional

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Cyclophosphamide, Abatacept, Tacrolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 28, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424
View directory record Official record
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 28, 2026, 1:32 PM EDT